ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through this collaboration, GSK will leverage Grabody-B ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases. The global licensing deal will allow GSK to use ABL Bio’s blood-brain barrier (BBB) ...

GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more. 1. Congressional commission urges $15B, more action to maintain US biotech advantage over China The U.S ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary ...